SCHEMBL2153170

SCHEMBL2153170

Cc1cn(CC(=O)N(C(C)NC(=O)OC(C)(C)C)[C@@H](C)C(=O)O)c(=O)[nH]c1=O

nearest known ligand 0.38

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TK1 P04183 7/20 0.37
TYMP P19971 2/20 0.36
HPGD P15428 1/20 0.36
TK2 O00142 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2685934 1.00 TK1 (0.37) TK1TYMPHPGDTK2
SCHEMBL9328006 1.00 TK1 (0.37) TK1TYMPHPGDTK2
SCHEMBL2153594 0.91 TK1 (0.39) TK1TYMPHPGD
SCHEMBL2161843 0.91 TK1 (0.39) TK1TYMPHPGD
SCHEMBL8642049 0.82 TK1 (0.39) TK1TYMPHPGDTK2
SCHEMBL6931032 0.80 TK1 (0.38) TK1TYMPHPGDTK2
SCHEMBL6513732 0.80 TK1 (0.38) TK1TYMPHPGDTK2
SCHEMBL6924139 0.80 SLC9A1 (0.40)
SCHEMBL6931025 0.80 SLC9A1 (0.40)
SCHEMBL2153131 0.80 TK1 (0.37) TK1TYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115136-A1 PNA DIAGNOSTIC USE PNA Patent Owners (a/k/a CIG) (US) 2012-05-10 US disclosed
EP-1074559-B1 Peptide nucleic acids BUCHARDT OLE (DK) 2011-07-06 EP disclosed
US-7378485-B2 Peptide nucleic acids with polyamide-containing backbones BUCHARDT OLE 2008-05-27 US disclosed
US-20060046255-A1 Use of nucleic acid analogues in diagnostics and analytical procedures BUCHARDT OLE 2006-03-02 US disclosed
EP-0960121-B1 PEPTIDE NUCLEIC ACIDS HAVING ENHANCED BINDING AFFINITY, SEQUENCE SPECIFICITY AND SOLUBILITY BUCHARDT DORTE (DK) 2005-11-30 EP disclosed
US-20050009041-A1 Peptide nucleic acids and synthetic procedures therefor BUCHARDT OLE (DK) 2005-01-13 US disclosed
EP-1411063-A1 Peptide nucleic acids BUCHARDT, Ole (DK) 2004-04-21 EP disclosed
US-6713602-B1 COMPOUNDS THAT ARE NOT POLYNUCLEOTIDES YET WHICH BIND TO COMPLEMENTARY DNA AND RNA STRANDS MORE STRONGLY THE CORRESPONDING DNA BUCHARDT OLE (DK) 2004-03-30 US disclosed
US-6710163-B1 COMPOUNDS THAT BIND SINGLE-STRANDED DNA AND RNA STRANDS TO FORM STABLE HYBRIDS; BIND COMPLEMENTARY SINGLE-STRANDED DNA AND RNA STRANDS MORE STRONGLY THAN CORRESPONDING DNA BUCHARDT OLE (DK) 2004-03-23 US disclosed
US-6710164-B1 COMPRISING AT LEAST ONE C1-C8 ALKYLAMINE SIDE CHAIN NIELSEN PETER E (DK) 2004-03-23 US disclosed
EP-1074559-A1 Peptide nucleic acids BUCHARDT, Ole (DK) 2001-02-07 EP disclosed
US-5786461-A Peptide nucleic acids having amino acid side chains BUCHARDT OLE (DK) 1998-07-28 US disclosed
US-5736336-A Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility BUCHARDT OLE (DK) 1998-04-07 US disclosed
US-5719262-A BIND COMPLEMENTARY DNA AND RNA STRANDS MORE STRONGLY BUCHARDT OLE (DK) 1998-02-17 US disclosed
US-5714331-A INCORPORATING AN AMINOALKYL SIDE CHAIN INTO THE PNA'S WHICH BIND TO COMPLEMENTARY NUCLEOBASE SEQUENCES MORE TIGHTLY TO FORM ?DUPLEXES?; VIRICIDES; ANTICARCINOGENIC AGENTS; ENZYME INHIBITORS EXXON CHEMICAL PATENT INC. 1998-02-03 US disclosed
EP-0586618-B1 THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES BUCHARDT DORTE (DK) 1997-07-16 EP disclosed
US-5539082-A Peptide nucleic acids NIELSEN PETER E (DK) 1996-07-23 US disclosed
EP-0586618-A1 THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES. BUCHARDT OLE (DK) 1994-03-16 EP disclosed
WO-1992020703-A1 THE USE OF NUCLEIC ACID ANALOGUES IN DIAGNOSTICS AND ANALYTICAL PROCEDURES BUCHARDT OLE (DK) 1992-11-26 WO disclosed
WO-1992020702-A1 PEPTIDE NUCLEIC ACIDS BUCHARDT OLE (DK) 1992-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115136-A1 PNA DIAGNOSTIC USE RNASE1, NCL, PABPC4 TK1 1839/4885TYMP 423/4885HPGD 3175/4885
US-20050009041-A1 Peptide nucleic acids and synthetic procedures therefor POLRMT, CPSF7, RNGTT TK1 290/4885TYMP 187/4885HPGD 4345/4885
US-20060046255-A1 Use of nucleic acid analogues in diagnostics and analytical procedures ADAR, POLRMT, POLI TK1 261/4885TYMP 48/4885HPGD 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.